TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line

Key Takeaways TG Therapeutics reported Q4 EPS of 14 cents, missing estimates despite 78% revenue growth.Briumvi recorded $189.1M in Q4 revenues, with U.S. net sales rising 76% Y/Y and 20% sequentially.TGTX reaffirmed 2026 revenue guidance of $875M-$900M, with Briumvi sales expected to be $825-$850M.TG Therapeutics (TGTX) reported earnings of 14 cents per share for the fourth quarter of 2025, which substantially missed the Zacks Consensus Estimate of 35 cents. The company had reported earnings of 15 cents pe ...